Localized Scleroderma Cutaneous Assessment Tool (LOSCAT)
Use this clinical tool to calculate the Localized Scleroderma Cutaneous Assessment Tool (LOSCAT) score to assess cutaneous disease activity and damage in patients presenting with localized scleroderma (morphea). This assessment evaluates patients across 18 separate anatomical sites by combining two discrete, validated scoring frameworks: the modified Localized Scleroderma Skin Severity Index (mLoSSI) for tracking active inflammation, and the Localized Scleroderma Skin Damage Index (LoSDI) for tracking structural sequelae. This comprehensive evaluation provides an objective matrix to direct systemic immunomodulatory treatments and map clinical progression.
The Pathophysiology and Clinical Role of LOSCAT
Localized Scleroderma, or morphea, is a chronic, immune-mediated inflammatory connective tissue disorder characterized by localized vascular damage, auto-antibody production, and excessive collagen deposition within the dermis and subcutaneous tissues. The early active stage is driven by a localized inflammatory infiltrate consisting of T-helper 1 and T-helper 17 cells, which secrete pro-inflammatory cytokines that stimulate local fibroblasts. This results in the characteristic indurated plaques with a distinct violaceous peripheral halo. Over time, active inflammation subsides, leading to the late sclerotic and atrophic phase, where healthy dermal architecture is replaced by dense hyalinized collagen bundles and subcutaneous adipose tissue is destroyed.
Because localized scleroderma is highly dynamic, a patient's lesions can simultaneously exhibit signs of active inflammation and irreversible structural damage on different parts of the body. Historically, monitoring was purely subjective, frequently leading to clinical errors such as continuing aggressive systemic immunosuppression for inactive atrophic scars, or prematurely stopping treatments while active subclinical disease continued to expand.
The LOSCAT addresses this challenge by completely decoupling the assessment of active disease from irreversible structural damage. This allows clinicians to accurately track disease velocity, make objective decisions regarding therapeutic escalation (such as introducing methotrexate or systemic corticosteroids), and monitor longitudinal response to treatment.
Scoring Architecture and Clinical Framework
The LOSCAT systematically evaluates 18 anatomical sites across the human body:
Head and Neck
Chest
Abdomen
Upper Back
Lower Back
Buttocks
Right Upper Arm and Left Upper Arm
Right Forearm and Left Forearm
Right Hand and Left Hand
Right Thigh and Left Thigh
Right Lower Leg and Left Lower Leg
Right Foot and Left Foot
Within each of these 18 sites, the clinician independently evaluates three active markers for the mLoSSI profile and three structural sequelae markers for the LoSDI profile.
1. Disease Activity: The mLoSSI Profile
The modified Localized Scleroderma Skin Severity Index (mLoSSI) tracks the intensity of active inflammation. Each parameter is graded on a scale from 0 to 3:
Erythema (ER): Grade 0 is normal skin; Grade 1 is slight redness or pinkness; Grade 2 is moderate, clear redness; Grade 3 is intense, dark red or deep violaceous discoloration.
Skin Thickness (ST): Grade 0 is normal skin thickness; Grade 1 is a mild increase in thickness with intact skin pliability; Grade 2 is a moderate increase in thickness with distinct stiffness; Grade 3 is maximum, severe skin thickness that is completely rigid and unyielding.
New Lesion / Lesion Extension (NE): Checked within the past month. Unlike other parameters, this is scored binary as either 0 (absent) or 1 (present).
The maximum possible mLoSSI score is 126.
2. Disease Damage: The LoSDI Profile
The Localized Scleroderma Skin Damage Index (LoSDI) tracks permanent structural changes left behind after inflammation resolves. Each parameter is graded on a scale from 0 to 3:
Dermal Atrophy (DA): Grade 0 is normal skin; Grade 1 is mild atrophy, visible as fine wrinkling or loss of normal skin markings; Grade 2 is moderate atrophy with distinct skin thinning and visible underlying vessels; Grade 3 is severe dermal atrophy with complete loss of dermal volume.
Subcutaneous Atrophy (SA): Grade 0 is normal tissue volume; Grade 1 is mild, shallow flattening or depression; Grade 2 is moderate, clear loss of fat volume forming a distinct clinical crater; Grade 3 is deep, maximum tissue loss exposing bone, muscle, or deep fascial planes.
Dyspigmentation (DP): Grade 0 is normal skin color; Grade 1 is mild hyper- or hypopigmentation; Grade 2 is moderate, clearly noticeable color changes; Grade 3 is severe, highly disfiguring pigmentary distortion.
The maximum possible LoSDI score is 162.
Interpretation and Therapeutic Significance
The LOSCAT calculations yield two distinct absolute numbers that dictate specific clinical pathways:
Elevated Activity (High mLoSSI / Stable LoSDI): Indicates a states of active, aggressive inflammation. This finding mandates initiating or intensifying systemic immunomodulatory therapies, such as methotrexate or systemic corticosteroid pulse therapy, to halt active progression and prevent subsequent permanent damage.
Elevated Damage (Zero mLoSSI / High LoSDI): Indicates stable, inactive burn-out disease with residual structural sequelae. Systemic immunosuppression provides no therapeutic benefit in this scenario and should be tapered or discontinued. Clinical focus should pivot entirely to physical therapy, cosmetic reconstruction, or monitoring for deep orthopedic changes.
Important Clinical Nuances and Assessment Pitfalls
To preserve the accuracy and utility of the LOSCAT during patient care, clinicians must keep several practical nuances in mind:
The Global Zero-Out Check: Because localized scleroderma typically presents as localized plaques rather than widespread generalized lesions, healthy and uninvolved anatomical areas will naturally score zeroes across all categories. Clinicians can utilize the "Mark All Uninvolved" function to rapidly set all 108 parameters to 0, subsequently adjusting only the specific regions containing active lesions.
The Deep Fascial Linearity Boundary: In linear variants of localized scleroderma (such as en coup de sabre or linear scleroderma of the limbs), the fibrotic process frequently extends far beneath the dermis, tethering tightly to underlying muscles, tendons, and joints. Because the standard LOSCAT focuses primarily on the skin layers, severe deep-tissue restriction can occasionally occur alongside a lower dermal score. In these linear cohorts, clinicians must perform formal joint mobility examinations and deep imaging alongside the tool.
Inter-Observer Tactile Variability: Subjective estimation of mild vs. moderate skin thickness or dermal atrophy requires substantial clinical experience and introduces inter-observer variability. To maintain longitudinal precision and verify true trends during treatment, a patient's score should ideally be assessed by the same clinician at each subsequent visit.
The Post-Inflammatory Dyspigmentation Delusion: As aggressive morphea plaques enter remission, they frequently leave behind flat, deep brown macular hyperpigmentation or areas of hypopigmentation. If an evaluator mistakenly interprets this post-inflammatory pigment change as active erythema, the computed mLoSSI score will remain artificially elevated, potentially leading to the unnecessary prolongation of systemic immunosuppressive therapies.
Authoritative Dermatological and Rheumatological References
Arkachaisri, T., Vilaiyuk, S., Li, S., et al. (2010). The Localized Scleroderma Cutaneous Assessment Tool (LOSCAT): responsive to change in a 12-month prospective study. Rheumatology, 49(11), 2181-2188.
Kelsey, C. E., & Torok, K. S. (2013). The Localized Scleroderma Cutaneous Assessment Tool: multi-rater reliability study. British Journal of Dermatology, 169(3), 684-687.
Zulian, F., Culpo, R., & Castela, E. (2019). International consensus recommendations for the evaluation and management of localized scleroderma in children and adults. Annals of the Rheumatic Diseases, 78(10), 1301-1308.
Got any Suggestion?
Contact:
info@histamind.com